Symbol="XFOR"
AssetType="Common Stock"
Name="X4 Pharmaceuticals Inc"
Description="X4 Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the research, development, and commercialization of new therapies for the treatment of back diseases. The company is headquartered in Boston, Massachusetts."
CIK="1501697"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)"
Address="955 MASSACHUSETTS AVENUE, 4TH FLOOR, CAMBRIDGE, MA, US"
FiscalYearEnd="December"
LatestQuarter="2023-06-30"
MarketCapitalization="207175000"
EBITDA="-100339000"
PERatio="None"
PEGRatio="None"
BookValue="0.411"
DividendPerShare="0"
DividendYield="0"
EPS="-0.74"
RevenuePerShareTTM="0"
ProfitMargin="0"
OperatingMarginTTM="0"
ReturnOnAssetsTTM="-0.495"
ReturnOnEquityTTM="-2.672"
RevenueTTM="0"
GrossProfitTTM="3000000"
DilutedEPSTTM="-0.74"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="0"
AnalystTargetPrice="3.64"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="53.87"
PriceToBookRatio="1.041"
EVToRevenue="50.06"
EVToEBITDA="-0.252"
Beta="0.235"
num_52WeekHigh="2.575"
num_52WeekLow="0.65"
num_50DayMovingAverage="1.727"
num_200DayMovingAverage="1.397"
SharesOutstanding="164425000"
DividendDate="2019-03-14"
ExDividendDate="None"
symbol="XFOR"
open="1.31"
high="1.36"
low="1.24"
price="1.26"
volume="1805613.00"
latest_trading_day="2023-08-24"
previous_close="1.28"
change="-0.02"
change_percent="-1.5625%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="17"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="83"
Volume_recent_avg="3532674"
Change_recent_avg="0.01"
Delta_recent_avg="0.16"
Variance_recent_avg="0.08"
Change_ratio_recent_avg="0.04"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="83"
Aroon_momentum_negative="17"
image_negative_thumbnail_id_1="513"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0092.jpeg"
image_negative_thumbnail_id_2="130"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0046.jpeg"
image_neutral_thumbnail_id_1="559"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0040.jpeg"
image_neutral_thumbnail_id_2="573"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0026.jpeg"
image_positive_thumbnail_id_1="952"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0114.jpeg"
image_positive_thumbnail_id_2="618"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0090.jpeg"
image_professor_thumbnail_id_1="1191"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0025.jpeg"
image_professor_thumbnail_id_2="1200"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0034.jpeg"
